Avantra | GenomeWeb

Avantra

Avantra said that TD2's pharma clients could use its platform to identify appropriate biomarkers for use with drugs in development.

New Product Watch

Premium

Avantra Biosciences' Q400 Biomarker Workstation and Angio Qx BioChip Immunoassay, Akonni Biosystems' TruSentry System, Agilent Technologies' BenchBot Robot, Exiqon's Mircury LNA microRNA Labeling Kits

Avantra was founded last year by Courtagen Capital Group to commercialize the assets of Decision Biomarkers, a protein biomarker technology firm that shuttered its business and filed for Chapter 7 bankruptcy in December 2009.

Formed from what had been Decision Biomarkers, Avantra is eyeing a launch of its biomarker detection platform in early 2011.

The company is being launched by Courtagen Capital Group using assets from defunct biotech firm Decision Biomarkers, which Courtagen purchased in bankruptcy court last December.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.